Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2190-2198

  Pirollo, Kathleen F ^a   Rait, Antonina ^a   Zhou, Qi ^a   Zhang, Xin Qiao ^b   Zhou, Jain ^b   Kim, Chang Soo ^b   Benedict, William F ^b   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; LIPOSOME; PROTEIN RB94; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERRIN; TRANSFERRIN RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; LIPOSOMES; MICE; NANOTECHNOLOGY; POLYMERASE CHAIN REACTION; RETINOBLASTOMA PROTEIN; TRANSFECTION; TRANSFERRIN; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42249100205     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1951     Document Type: Article

References (41)

1. Huang L, Viroonchatapan E. Introduction. In: Huang L, Hung M, Wagner E, editors. Non-viral vectors for gene therapy. San Diego: Academic Press; 1999. p. 3- 22.
2. Lasic DD, Papahadjopoulos D. General Introduction. In: Lasic DD, Papahadjopoulos D, editors. Medical applications of liposomes. Amsterdam: Elsevier; 1998. p. 1-9.
3. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2:369-81.
4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
5. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 2006;116:255-64.
6. Cristiano RJ, Curiel DT. Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cancer Gene Ther 1996;3:49-57.
7. Cheng PW. Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferring. Hum Gene Ther 1996;7:275-82.
8. Thorstensen K, Romslo I. The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand J Clin Lab Inves 1993;215:113-20.
9. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999;31:1111-37.
10. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des 1999;5:443-51.
11. Seymour GJ, Walsh MD, Lavin MF, Strutton G, Gardiner RA. Transferrin receptor expression by human bladder transitional cell carcinomas. Neurol Res 1987;15:341-4.
12. Derycke AS, Kamuhabwa A, Gijsens A, et al. Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells. J Natl Cancer Inst 2004;96:1620-30.
13. Baar I, Ayhan A, Bircan K, Ergen A, Taar C. Transferrin receptor activity as a marker in transitional cell carcinoma of the bladder. Br J Urol 1991;67:165-8.
14. Rahman SA, Yokoyama M, Nishio S, Takeuchi M. Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma. Neurol Res 1997;25:325-9.
15. Smith NW, Strutton GM, Walsh MD, et al. Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences. Br J Urol 1990;65:339-44.
16. Xu L, Pirollo K, Tang W, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999;10:2941-52.
17. Xu L, Pirollo KF, Chang EH. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 1997;8:467-75.
18. Xu L, Pirollo K, Rait A, Murray A, Chang EH. Systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Targeting 1999;4:92-104.
19. Günther M, Wagner, E, Ogris M. Specific targets in tumor tissue for the delivery of therapeutic genes. Curr Med Chem Anti-Canc Agents 2005;5:157-71.
20. Dass CR, Choong PF. Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J Control Release 2006;113:155-63.
21. Park JW, Benz CC, Martin FJ. Future directions of liposome- andi mmunoliposome-based cancer therapeutics. Semin Oncol 2004;31:196-205.
22. Selvam MP, Buck SM, Blay RA, Mayner RE, Mied PA, Epstein JS. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res 1996;33:11-20.
23. Pirollo KF, Xu L, Chang EH. Immunoliposomes: a targetedd elivery tool for cancer treatment. In: Curiel D, editor. Vector targeting for therapeutic gene delivery. Hoboken (NJ): Wiley-Liss; 2002. p. 33-61.
24. Gunther M, Wagner E, Ogris M. Specific targets in tumor tissue for the delivery of therapeutic genes. Curr Med Chem Anti-Canc Agents 2005;5:157-71.
25. Poon RY. Advances in monoclonal antibody applications: bispecific antibodies. In: Fox F, Connor TH, editors. Biotechnology international: international developments in the biotechnology industry. San Francisco (CA): Universal Medical Press; 2000. p. 113-28.
26. Haynes BF, Hemler M, Cotner T, et al. Characterization of amonoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J Immunol 1981;127:347-51.
27. Batra JK, Fitzgerald DJ, Chaudhary VK, Pastan I. Single-chain immunotoxins directed at the human transferrin receptor containing pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cel Biol 1991;11:2200-5.
28. Xu L, Tang WH, Huang CC, et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol Med 2001;7:723-34.
29. Xu L, Huang CC, Huang WQ, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002;1:337-46.
30. Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006;17:117-24.
31. Pirollo KF, Rait A, Zhou Q, et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007;67:2938-43.
32. Pirollo KF, Dagata J, Wang P, et al. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging 2006;5:41-52.
33. Xu HJ, Xu K, Zhou Y, Li J, Benedict WF, Hu SX. Enhanced tumor cell growth suppression by an internal AUG codon initiated retinoblastoma protein. Proc Natl Acad Sci U S A 1994;91:9837-41.
34. Xu HJ, Zhou Y, Seigne J, et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996;56:2245-9.
35. Zhang X, Multani AS, Zhou JH, et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial ells but not in normal urothelial cells. Cancer Res 2003;63:760-5.
36. Yu W, Pirollo KF, Yu B, et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004;32:e48.
37. Watanabe T, Shinohara N, Sazawa A, et al. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 2000;7:1575-80.
38. Yamashita M, Rosser CJ, Zhou JH, et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 2002;9:687-91.
39. Jain RK, Baxter LT. Mechanisms of heterogenous distribution of monoclonal antibodies and other macro-molecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:7022-32.
40. Xu L, Frederik P, Pirollo KF, et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum Gene Ther 2002;13:469-81.
41. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004;10:2981-9.